Aldeyra Therapeutics Inc

NASDAQ:ALDX  
5.44
-0.33 (-5.72%)
Products, Earnings Announcements

Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting With FDA And Highlights Upcoming Corporate Milestones

Published: 09/14/2022 13:01 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-nda Meeting With FDA and Highlights Upcoming Corporate Milestones.
Aldeyra Therapeutics Inc - Dry Eye Disease NDA for Reproxalap Expected to Be Submitted in Q4 of 2022.
Aldeyra Therapeutics Inc - Results From Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy Expected in Third Or Q4 of 2022.
Aldeyra Therapeutics Inc - Esults From Phase 2 Clinical Trial of Adx-2191 in Retinitis Pigmentosa Expected in First Half of 2023.
Aldeyra Therapeutics Inc - Results From Phase 3 Invigorate-2 Trial of Reproxalap in Allergic Conjunctivitis Expected in 2023.
Aldeyra Therapeutics Inc - Pre-nda Meeting for Adx-2191 for Treatment of Primary Vitreoretinal Lymphoma Scheduled for Q4 of 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.34

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.39

More details on our Analysts Page.